Hyperleptinemia related to obesity promotes vascular inflammation and disrupts BBB integrity via JAK/STAT-dependent signaling pathways, and new therapies aimed at manipulating leptin, such as metreleptin antagonists, have shown significant promise for finding reductions in ICP associated with obesity-related IIH. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.